Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Linz – page 32

419 clinical trials in Linz, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Linz at a glance
419
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

419 trials in Linz

Open in trial search

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary arterial hypertension

Not recruiting

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Myelodysplastic syndrome

Not recruiting

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 1 diabetes mellitus

Not recruiting

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Prophylaxis against transplant rejection

Not recruiting

Study on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Medical University Of Vienna

Squamous cell carcinoma of head and neck

Not recruiting

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Anaemia+1

Not recruiting

Study of AG-946 for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AG-946
  • Sponsor:Agios Pharmaceuticals Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Linz

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on various forms of cancer, including prostate cancer, colorectal cancer, and lung cancer. Studies are evaluating novel therapeutic approaches and combination treatments.

  • Metastatic cancer treatments
  • Immunotherapy combinations
  • Novel drug therapies

Particular emphasis on personalized treatment approaches and targeted therapies for specific cancer types.

02 Autoimmune Conditions

Research targeting inflammatory and autoimmune disorders, including Crohn's Disease, plaque psoriasis, and uveitis. Studies evaluate new biological treatments and combination therapies.

  • Inflammatory disease management
  • Novel biological agents
  • Treatment resistance solutions

Focus on improving disease control and patient outcomes through innovative therapeutic approaches.

03 Cardiovascular and Metabolic Studies

Trials investigating treatments for cardiovascular disease and obesity, with emphasis on preventive measures and innovative therapeutic solutions.

  • Cardiovascular risk reduction
  • Metabolic disorder management
  • Safety assessments

Research aimed at developing safer and more effective treatments for metabolic and cardiovascular conditions.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.